Navigation Links
Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
Date:4/23/2009

FOXA1 biomarker predicts likelihood of recurrence and long-term disease-free survival of breast cancer patients; Further strengthens Company's breast cancer menu

ALISO VIEJO, Calif., April 23 /PRNewswire-FirstCall/ -- Clarient, Inc., (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has been granted an exclusive intellectual property license from the Indiana University Research and Technology Corporation (IURTC) for the rights to commercialize the FOXA1 biomarker, which predicts the likelihood of recurrence and long-term, disease-free breast cancer survival. The licensing of this intellectual property further strengthens Clarient's deep menu of molecular tests for breast cancer and will complement the Clarient Insight(R) Dx Breast Cancer Profile, which is expected to be released soon.

The FOXA1 marker, also known as forkhead box A1, is a gene known to cause breast cancer. Recent data presented at the 2009 USCAP (United States and Canadian Academy of Pathology) meeting demonstrated that the expression of FOXA1, now known to be an estrogen receptor associated transcription factor, correlated with Oncotype Dx(R) when performed in patient samples from Indiana University. In this clinical study of 79 ER-positive, node-negative breast cancer patients, researchers found that FOXA1 expression identified the same low risk, ER-positive, node-negative patients who can be spared toxic chemotherapy (P=0.002). Researchers concluded Oncotype Dx and the FOXA1 marker can potentially be used interchangeably if further validation studies confirm t
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
2. Clarient to Commercialize Novel Breast Cancer Profile
3. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
4. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
5. Jim Agnello to Resign as Clarient Chief Financial Officer
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
8. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
11. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015  RegeneRx Biopharmaceuticals, Inc. ... in the scientific journal, Expert Opinion on Biological ... colleague, Dr. Zhenggang Zhang , at the Henry ... reported that Thymosin beta 4 (TB4) has the capacity ... 24 hours or more post-injury, leading to neurological recovery ...
(Date:3/3/2015)... Corner, New Jersey (PRWEB) March 03, 2015 ... NJ, has announced today that it has acquired ... Terms of the transaction were not announced. ... consulting services to the energy sector including oil ... alternative energy, and fossil and nuclear power sectors. ...
(Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/gxqhg9/gene_therapy ... new report "Gene Therapy - Technologies, Markets ... Gene therapy technologies are described in ... therapy with genetically modified vectors. Gene therapy is ... routes of administration as well as targeted gene ...
(Date:3/3/2015)... MN , March 3, 2015 /PRNewswire/ - BioAmber ... company producing sustainable chemicals, today announced it has initiated ... plant located in Sarnia, Ontario , ... to take approximately five months, with the facility being ... construction to be completed in two months and it ...
Breaking Biology Technology:Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3BioAmber Begins Commissioning of Sarnia Commercial Plant 2BioAmber Begins Commissioning of Sarnia Commercial Plant 3
... Biological Sciences Research Council (BBSRC) have shown that past ... complex decisions based on uncertain or confusing information. They ... in our brains so that we can quickly categorise ... carry out appropriate actions. The research is published today ...
... charged method at Reproductive Science Center of the San ... In response to growing numbers of couples who want ... Reproductive Science Center of the San Francisco Bay Area ... alternative gender-selection technique with fewer moral and ethical dilemmas. ...
... May 13 SpectraScience, Inc. (OTC Bulletin Board: ... today announced that it has established a distribution ... Krainer Medtechnik, a Vienna-based firm specializing in the ... devices.Michel Vaudry, SpectraScience,s VP Sales and Marketing, commented, ...
Cached Biology Technology:Brain research shows past experience is invaluable for complex decision making 2Gender-Selection Technique Embraced for Hopeful Parents 2SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria 2SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria 3
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying ... power and potential for genomic science as a means ... disease prevention and treatment.  I was honored to participate ... government-funded precision medicine program. Since the ... science of genomics—from the first sequenced genome of a ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... will be crucial to buffer the negative effects of climate ... a new landmark study. The findings of the multi-author ... based on samples of ecosystems in every continent except Antarctica. ... diverse an ecosystem is, the more ecological functions it performs. ...
... published online in the FASEB Journal ( http://www.fasebj.org ... the intestines may be used to predict a person,s likelihood ... may help reduce heart attack risk. This discovery may lead ... prevent and treat heart attacks. In addition, this research suggests ...
... their foraging due to changes in wind fields in the ... in intensity and moved to the south, the flight speed ... a consequence, breeding success has improved and birds have gained ... an international research team published in the latest issue of ...
Cached Biology News:Diverse ecosystems are crucial climate change buffer 2The microbiome and disease: Gut bacteria influence the severity of heart attacks in rats 2Largest bird alters its foraging due to climate change 2Largest bird alters its foraging due to climate change 3
... (PTO) oligonucleotides: PTOs are internucleotide ... phosphate backbone is replaced by a sulphur ... nuclease degradation. PTOs are available as ... phosphothioates Oligonucleotides with thio-caps ...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
... S and 135 S steam sterilizers with their ... the advantages of a double-walled device - low ... and drying by built-in jacket heater - with ... The chamber is free of furnishings and feed ...
... RNase H- Reverse Transcriptase (RT) is an ... RT. It is a DNA polymerase that ... RNA DNA or an RNA:DNA hybrid. This ... of point mutations rather than a deletion ...
Biology Products: